iNGENu CRO, Quantum BioPharma to launch Australian trial for chronic nociplastic pain in MCAS patients
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
The trial targets MCAS/MCAD, an under-recognized, debilitating condition with an unknown cause and no cure
his is the second license extension of a Nurix autoimmune disease program by Sanofi in the last 90 days
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Revvity launches its first set of IVD Mimix reference standards, providing diagnostic labs with trusted quality controls for optimizing tests and monitoring workflows
Subscribe To Our Newsletter & Stay Updated